thymidine has been researched along with Hepatitis B in 69 studies
Hepatitis B: INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a prospective study of 450 hepatitis B e antigen-positive pregnant women with HBV DNA levels greater than 10(6) IU/mL; 279 women received telbivudine (600 mg/d) during weeks 24 to 32 of gestation, and 171 women who were unwilling to take antiviral drugs participated as controls." | 9.20 | Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study. ( Deng, G; He, D; He, Y; Huang, H; Li, J; Li, L; Pan, M; Sun, X; Tan, S; Wang, Y; Wu, Q; Yan, Z; Zeng, Y, 2015) |
| "There is limited data on the efficacy and outcome of telbivudine (LdT) therapy in patients with chronic hepatitis B and compensated cirrhosis." | 9.19 | Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis. ( Chang, KC; Chen, CH; Chiu, KW; Hu, TH; Hung, CH; Lee, CM; Lin, MT; Tsai, MC; Tseng, PL; Yen, YH; Yu, HC, 2014) |
| "To evaluate the efficacy and safety of telbivudine use during the second and third trimester of pregnancy for reducing hepatitis B virus (HBV) transmission from highly viremic hepatitis B e antigen-positive (HBeAg+) mothers to their fetuses." | 9.16 | [Efficacy and safety of telbivudine in pregnant women to prevent perinatal transmission of hepatitis B virus]. ( Han, GR; Jiang, HX; Kan, NY; Wang, CM; Wang, GJ; Wu, MM; Yue, X, 2012) |
| "The aim of this work was to compare the early antiviral effectiveness of telbivudine and entecavir in the treatment of patients with hepatitis B e antigen (HBeAg)-positive HBV." | 9.14 | A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. ( Chen, YP; Dai, ZJ; Shi, KQ; Ye, C; Zheng, MH, 2010) |
| "BECKGROUND: Evaluate the efficacy and safety of telbivudine during the 2nd and 3rd trimester of pregnancy in intrauterine transmission of hepatitis B virus (HBV)." | 8.90 | Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis. ( Chen, YP; Hocher, B; Huang, SM; Li, J; Liang, XJ; Liu, ZW; Lu, YP; Xiao, XM, 2014) |
| "To investigate postpartum hepatic flares and associated factors in highly viremic pregnant patients in the immune tolerance phase who adopted telbivudine (LdT) treatment in the last trimester to reduce vertical transmission of hepatitis B virus." | 8.02 | Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine. ( Chen, X; Hu, Z; Lu, J; Ma, L; Wang, X; Zheng, S; Zhu, Y, 2021) |
| " This study was conducted to compare the effectiveness of lamivudine (LMV), adefovir dipivoxil (ADV), telbivudine (LdT), and entecavir (ETV) monotherapy in chronic HBeAg-negative hepatitis B patients with medium load of HBV DNA." | 7.85 | Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels. ( Han, Z; Huang, M; Liu, J; Shi, H; Xia, J; Xue, J; Zhang, S; Zhu, Z, 2017) |
| "In our study, long-term telbivudine therapy is associated with a sustained improvement of renal function in patients with hepatitis B virus infection after living donor liver transplant." | 7.85 | A Follow-Up Study on the Renal Protective Efficacy of Telbivudine for Hepatitis B Virus-Infected Taiwanese Patients After Living Donor Liver Transplant. ( Chen, YL; Hsieh, CE; Ko, CJ; Lin, CC; Lin, KH; Lin, PY; Ming, YZ, 2017) |
| "To observe the success rate of telbivudine (LdT) for the prevention of perinatal transmission of hepatitis B virus (HBV) and the incidence of alanine aminotransferase (ALT) elevation during LdT treatment and after LdT withdrawal in HBV-infected pregnant woman with high viremia in immune-tolerant phase and receiving LdT treatment at the end of pregnancy, and to evaluate the efficacy of LdT in the prevention of perinatal transmission and the safety for pregnant women." | 7.83 | [Telbivudine for prevention of perinatal transmission in pregnant women infected with hepatitis B virus in immune-tolerant phase: a study of efficacy and safety of drug withdrawal]. ( Bai, H; Ding, Y; Dou, XG; Fan, YX; Han, C; Li, BJ; Li, YW; Sheng, QJ; Zhang, C, 2016) |
| "Data are limited for comparison of the long-term efficacy of telbivudine (LdT) between hepatitis B virus (HBV)-related compensated and decompensated cirrhosis." | 7.80 | Comparison of telbivudine efficacy in treatment-naive patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks. ( Li, J; Liu, J; Lu, W; Wang, J; Yang, X; Zhou, L, 2014) |
| "The aim of this study was to evaluate the efficacy and safety of telbivudine 600 mg/day compared with lamivudine 100 mg/day for 48 weeks of treatment in patients with hepatitis B-related cirrhosis." | 7.79 | Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis. ( Chen, Y; Gao, Z; Han, Y; Han, Z; Jia, G; Li, C; Liu, J; Luo, G; Shi, Y; Xia, L; Yin, F; Zhou, X; Zhu, J, 2013) |
| "Tenofovir is a new effective treatment option for patients with chronic hepatitis B, but could be potentially hampered by mutations in the hepatitis B virus (HBV) polymerase conferring drug resistance." | 7.75 | The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. ( Amini-Bavil-Olyaee, S; Herbers, U; Luedde, T; Sheldon, J; Tacke, F; Trautwein, C, 2009) |
| "beta-L-Thymidine (L-dT) and beta-L-2'-deoxycytidine (L-dC) are potent and highly specific inhibitors of hepatitis B virus (HBV) replication both in vivo and in vitro (50% effective concentrations, 0." | 7.71 | Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. ( Bridges, EG; Bryant, ML; Cretton-Scott, E; Dukhan, D; Faraj, A; Gosselin, G; Hernandez-Santiago, B; Imbach, JL; Pierra, C; Placidi, L; Rodriguez-Orengo, J; Sommadossi, JP, 2002) |
| "An inhibitory effect of 3'-azido-3'-deoxythymidine triphosphate on hepatitis B virus DNA polymerase was found." | 7.67 | Inhibition of hepatitis B virus DNA polymerase by 3'-azido-3'-deoxythymidine triphosphate but not by its threo analog. ( Chattopadhyaya, J; Löfgren, B; Nordenfelt, E; Oberg, B, 1987) |
| " LdT treatment was safe for mothers and infants, and no congenital deformities were reported." | 5.42 | Efficacy and safety of telbivudine treatment: an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection. ( Ding, Y; Han, GR; Jiang, HX; Wang, CM; Wang, GJ; Yang, YF; Yue, X, 2015) |
| "We performed a prospective study of 450 hepatitis B e antigen-positive pregnant women with HBV DNA levels greater than 10(6) IU/mL; 279 women received telbivudine (600 mg/d) during weeks 24 to 32 of gestation, and 171 women who were unwilling to take antiviral drugs participated as controls." | 5.20 | Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study. ( Deng, G; He, D; He, Y; Huang, H; Li, J; Li, L; Pan, M; Sun, X; Tan, S; Wang, Y; Wu, Q; Yan, Z; Zeng, Y, 2015) |
| "There is limited data on the efficacy and outcome of telbivudine (LdT) therapy in patients with chronic hepatitis B and compensated cirrhosis." | 5.19 | Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis. ( Chang, KC; Chen, CH; Chiu, KW; Hu, TH; Hung, CH; Lee, CM; Lin, MT; Tsai, MC; Tseng, PL; Yen, YH; Yu, HC, 2014) |
| "To evaluate the efficacy and safety of telbivudine use during the second and third trimester of pregnancy for reducing hepatitis B virus (HBV) transmission from highly viremic hepatitis B e antigen-positive (HBeAg+) mothers to their fetuses." | 5.16 | [Efficacy and safety of telbivudine in pregnant women to prevent perinatal transmission of hepatitis B virus]. ( Han, GR; Jiang, HX; Kan, NY; Wang, CM; Wang, GJ; Wu, MM; Yue, X, 2012) |
| "The aim of this work was to compare the early antiviral effectiveness of telbivudine and entecavir in the treatment of patients with hepatitis B e antigen (HBeAg)-positive HBV." | 5.14 | A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. ( Chen, YP; Dai, ZJ; Shi, KQ; Ye, C; Zheng, MH, 2010) |
| "The aim of this prospective study was to investigate the diagnostic value of ultrasound elastography for evaluating liver stiffness measurement (LSM) in 74 patients with hepatitis B virus (HBV) infection, treated with telbivudine (22 with chronic HBV infection, 32 with compensated cirrhosis and 20 with decompensated cirrhosis)." | 5.14 | The diagnostic value of ultrasound elastography in patients with hepatitis B virus infection: a prospective study. ( Bai, XF; Gou, YZ; Jiang, W; Liu, B; Yu, HT, 2010) |
| "BECKGROUND: Evaluate the efficacy and safety of telbivudine during the 2nd and 3rd trimester of pregnancy in intrauterine transmission of hepatitis B virus (HBV)." | 4.90 | Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis. ( Chen, YP; Hocher, B; Huang, SM; Li, J; Liang, XJ; Liu, ZW; Lu, YP; Xiao, XM, 2014) |
| " In the last few years the therapeutic options in chronic hepatitis B have increased and currently six treatments are authorized: standard interferon (IFN)-alpha, pegylated interferon-alpha (PEG-IFNalpha), lamivudine, adefovir, entecavir, and telbivudine." | 4.84 | [Interferon in hepatitis B]. ( García Buey, L; González Mateos, F; Moreno Otero, R, 2008) |
| "Idenix (formerly Novirio) and Novartis are developing two beta-L-deoxynucleosides, telbivudine and torcitabine, for the potential treatment of hepatitis B virus infection." | 4.82 | Telbivudine/Torcitabine Idenix/Novartis. ( Hodge, RA, 2004) |
| "To investigate postpartum hepatic flares and associated factors in highly viremic pregnant patients in the immune tolerance phase who adopted telbivudine (LdT) treatment in the last trimester to reduce vertical transmission of hepatitis B virus." | 4.02 | Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine. ( Chen, X; Hu, Z; Lu, J; Ma, L; Wang, X; Zheng, S; Zhu, Y, 2021) |
| " This study was conducted to compare the effectiveness of lamivudine (LMV), adefovir dipivoxil (ADV), telbivudine (LdT), and entecavir (ETV) monotherapy in chronic HBeAg-negative hepatitis B patients with medium load of HBV DNA." | 3.85 | Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels. ( Han, Z; Huang, M; Liu, J; Shi, H; Xia, J; Xue, J; Zhang, S; Zhu, Z, 2017) |
| "In our study, long-term telbivudine therapy is associated with a sustained improvement of renal function in patients with hepatitis B virus infection after living donor liver transplant." | 3.85 | A Follow-Up Study on the Renal Protective Efficacy of Telbivudine for Hepatitis B Virus-Infected Taiwanese Patients After Living Donor Liver Transplant. ( Chen, YL; Hsieh, CE; Ko, CJ; Lin, CC; Lin, KH; Lin, PY; Ming, YZ, 2017) |
| "To observe the success rate of telbivudine (LdT) for the prevention of perinatal transmission of hepatitis B virus (HBV) and the incidence of alanine aminotransferase (ALT) elevation during LdT treatment and after LdT withdrawal in HBV-infected pregnant woman with high viremia in immune-tolerant phase and receiving LdT treatment at the end of pregnancy, and to evaluate the efficacy of LdT in the prevention of perinatal transmission and the safety for pregnant women." | 3.83 | [Telbivudine for prevention of perinatal transmission in pregnant women infected with hepatitis B virus in immune-tolerant phase: a study of efficacy and safety of drug withdrawal]. ( Bai, H; Ding, Y; Dou, XG; Fan, YX; Han, C; Li, BJ; Li, YW; Sheng, QJ; Zhang, C, 2016) |
| "Data are limited for comparison of the long-term efficacy of telbivudine (LdT) between hepatitis B virus (HBV)-related compensated and decompensated cirrhosis." | 3.80 | Comparison of telbivudine efficacy in treatment-naive patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks. ( Li, J; Liu, J; Lu, W; Wang, J; Yang, X; Zhou, L, 2014) |
| "Myopathy or neuropathy has been associated with lamivudine/telbivudine therapy in hepatitis B patients." | 3.80 | Lamivudine/telbivudine-associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion. ( Jin, S; Lv, H; Wang, Z; Xu, H; Yuan, Y; Zhang, W; Zheng, L, 2014) |
| "The aim of this study was to evaluate the efficacy and safety of telbivudine 600 mg/day compared with lamivudine 100 mg/day for 48 weeks of treatment in patients with hepatitis B-related cirrhosis." | 3.79 | Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis. ( Chen, Y; Gao, Z; Han, Y; Han, Z; Jia, G; Li, C; Liu, J; Luo, G; Shi, Y; Xia, L; Yin, F; Zhou, X; Zhu, J, 2013) |
| "Telbivudine (beta-l-2'-deoxythymidine) is an orally administered nucleoside analog drug approved for the treatment of patients with chronic hepatitis B since 2006." | 3.77 | Rhabdomyolysis in a 48-year-old man with hepatitis B-induced cirrhosis. ( Dang, S; Gao, N; Jia, X; Zhang, X, 2011) |
| "A 27 yo male of African origin received telbivudine for hepatitis B during 3 months." | 3.76 | Myotoxicity of telbivudine in pre-existing muscle damage. ( Ay, L; Finsterer, J, 2010) |
| "Tenofovir is a new effective treatment option for patients with chronic hepatitis B, but could be potentially hampered by mutations in the hepatitis B virus (HBV) polymerase conferring drug resistance." | 3.75 | The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. ( Amini-Bavil-Olyaee, S; Herbers, U; Luedde, T; Sheldon, J; Tacke, F; Trautwein, C, 2009) |
| "beta-L-Thymidine (L-dT) and beta-L-2'-deoxycytidine (L-dC) are potent and highly specific inhibitors of hepatitis B virus (HBV) replication both in vivo and in vitro (50% effective concentrations, 0." | 3.71 | Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. ( Bridges, EG; Bryant, ML; Cretton-Scott, E; Dukhan, D; Faraj, A; Gosselin, G; Hernandez-Santiago, B; Imbach, JL; Pierra, C; Placidi, L; Rodriguez-Orengo, J; Sommadossi, JP, 2002) |
| "An inhibitory effect of 3'-azido-3'-deoxythymidine triphosphate on hepatitis B virus DNA polymerase was found." | 3.67 | Inhibition of hepatitis B virus DNA polymerase by 3'-azido-3'-deoxythymidine triphosphate but not by its threo analog. ( Chattopadhyaya, J; Löfgren, B; Nordenfelt, E; Oberg, B, 1987) |
| "The incorporation of 14C-thymidine by peripheral blood lymphocytes stimulated by phytohemagglutinin (PHA) and the proportion and absolute number of E-rosettes were determined in 28 prostitutes and the results were correlated with hepatitis B virus (HBV) serology." | 3.66 | T-lymphocytes and hepatitis B serology. ( Drouga, M; Kaklamani, E; Karalis, D; Papaevangelou, G; Papoutsakis, G; Trichopoulos, D, 1978) |
| "In patients not requiring HAART, treatment of hepatitis B should preferably consist of drugs without activity against HIV, such as pegylated interferon or adefovir." | 2.44 | [Hepatitis B in patients with HIV infection]. ( Barreiro, P; García-Samaniego, J; Martín-Carbonero, L, 2008) |
| "Lamivudine was switched to telbivudine." | 1.42 | Telbivudine in liver transplant recipients: Renal protection does not overcome the risk of polyneuropathy and myopathy. ( Akarca, US; Bademkiran, F; Duman, S; Ersoz, G; Gunsar, F; Karasu, Z; Kose, T; Ozutemiz, O; Sozbilen, M; Turan, I; Yapali, S, 2015) |
| " LdT treatment was safe for mothers and infants, and no congenital deformities were reported." | 1.42 | Efficacy and safety of telbivudine treatment: an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection. ( Ding, Y; Han, GR; Jiang, HX; Wang, CM; Wang, GJ; Yang, YF; Yue, X, 2015) |
| "This retrospective investigation carried out in Guangdong Province indicated that not only are anti-HBV drugs efficacious for blocking vertical transmission of HBV but also are safe for both mothers and infants when taken by fathers or mothers during the reproduction phases of insemination and pregnancy." | 1.40 | [Retrospective analysis of the efficacy and safety of anti-hepatitis B virus drugs taken during pregnancy in women from the Guangdong Province]. ( Chen, X; Gao, W; Li, D; Peng, J; Wen, F; Xia, J; Xu, C; Xu, M; Yao, Z, 2014) |
| "Telbivudine seemed to be a candidate for exclusive anti-HBV therapy because it exerts no significant in vitro activity against HIV." | 1.39 | In vivo antiviral activity of telbivudine against HIV-1: a case report. ( Bonadies, G; Borgia, G; Borrelli, F; Buonomo, AR; Carleo, MA; Gentile, I; Portella, G, 2013) |
| "Hepatitis B virus (HBV) recurrence after orthotopic liver transplantation (OLT) represents a severe condition that requires prophylaxis with specific immunoglobulin and lamivudine." | 1.38 | Telbivudin as prophylaxis for hepatitis B virus recurrence after liver transplantation: a case series in single-center experience. ( Amato, G; Calise, F; Cuomo, O; Dicostanzo, G; Lanza, AG; Marcos, A; Perrella, A; Pisaniello, D; Santaniello, W, 2012) |
| "Hepatitis B is a DNA virus affecting hundreds of millions of individuals worldwide." | 1.36 | Viral resistance in hepatitis B: prevalence and management. ( Chee, GM; Poordad, F, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (21.74) | 18.7374 |
| 1990's | 1 (1.45) | 18.2507 |
| 2000's | 11 (15.94) | 29.6817 |
| 2010's | 41 (59.42) | 24.3611 |
| 2020's | 1 (1.45) | 2.80 |
| Authors | Studies |
|---|---|
| Li, D | 2 |
| Huang, ZM | 1 |
| Lu, J | 1 |
| Wang, X | 1 |
| Zhu, Y | 1 |
| Ma, L | 1 |
| Zheng, S | 1 |
| Hu, Z | 1 |
| Chen, X | 2 |
| Shi, H | 1 |
| Han, Z | 2 |
| Liu, J | 3 |
| Xue, J | 1 |
| Zhang, S | 1 |
| Zhu, Z | 1 |
| Xia, J | 2 |
| Huang, M | 2 |
| Lin, CL | 1 |
| Kao, JH | 1 |
| Shi, Y | 1 |
| Zhu, J | 1 |
| Chen, Y | 1 |
| Yin, F | 1 |
| Xia, L | 1 |
| Luo, G | 1 |
| Gao, Z | 2 |
| Jia, G | 1 |
| Li, C | 1 |
| Zhou, X | 1 |
| Han, Y | 1 |
| Lisotti, A | 1 |
| Eusebi, LH | 1 |
| Festi, D | 1 |
| Bazzoli, F | 1 |
| Mazzella, G | 1 |
| Gentile, I | 1 |
| Bonadies, G | 1 |
| Carleo, MA | 1 |
| Buonomo, AR | 1 |
| Borrelli, F | 1 |
| Portella, G | 1 |
| Borgia, G | 1 |
| Calvaruso, V | 1 |
| Craxì, A | 1 |
| Yang, X | 1 |
| Li, J | 4 |
| Zhou, L | 1 |
| Wang, J | 1 |
| Lu, W | 1 |
| Tsai, MC | 1 |
| Yu, HC | 1 |
| Hung, CH | 1 |
| Lee, CM | 1 |
| Chiu, KW | 1 |
| Lin, MT | 1 |
| Tseng, PL | 1 |
| Chang, KC | 1 |
| Yen, YH | 1 |
| Chen, CH | 1 |
| Hu, TH | 1 |
| Lu, YP | 1 |
| Liang, XJ | 1 |
| Xiao, XM | 1 |
| Huang, SM | 1 |
| Liu, ZW | 1 |
| Hocher, B | 1 |
| Chen, YP | 2 |
| Tillmann, HL | 1 |
| Patel, K | 1 |
| Xu, H | 1 |
| Wang, Z | 1 |
| Zheng, L | 1 |
| Zhang, W | 1 |
| Lv, H | 1 |
| Jin, S | 1 |
| Yuan, Y | 1 |
| Peng, J | 1 |
| Xu, M | 1 |
| Yao, Z | 1 |
| Xu, C | 1 |
| Wen, F | 1 |
| Gao, W | 1 |
| Wu, Q | 1 |
| Huang, H | 1 |
| Sun, X | 1 |
| Pan, M | 1 |
| He, Y | 1 |
| Tan, S | 1 |
| Zeng, Y | 1 |
| Li, L | 1 |
| Deng, G | 1 |
| Yan, Z | 1 |
| He, D | 1 |
| Wang, Y | 1 |
| Han, GR | 2 |
| Jiang, HX | 2 |
| Yue, X | 2 |
| Ding, Y | 2 |
| Wang, CM | 2 |
| Wang, GJ | 2 |
| Yang, YF | 1 |
| Hollinger, FB | 1 |
| Turan, I | 1 |
| Yapali, S | 1 |
| Bademkiran, F | 1 |
| Kose, T | 1 |
| Duman, S | 1 |
| Sozbilen, M | 1 |
| Gunsar, F | 1 |
| Ersoz, G | 1 |
| Akarca, US | 1 |
| Ozutemiz, O | 1 |
| Karasu, Z | 1 |
| Su, F | 1 |
| Dai, J | 2 |
| Yang, S | 1 |
| Jiang, X | 1 |
| Cui, X | 1 |
| Ning, H | 1 |
| Zhang, Y | 1 |
| Hu, P | 1 |
| Qi, X | 1 |
| Ren, H | 1 |
| Mao, RC | 1 |
| Zhang, JM | 1 |
| Zhang, MY | 1 |
| Zhu, GQ | 1 |
| Shi, KQ | 2 |
| Zheng, JN | 1 |
| Cheng, Z | 1 |
| Zou, ZL | 1 |
| Huang, HH | 1 |
| Chen, FY | 1 |
| Zheng, MH | 2 |
| Sheng, QJ | 1 |
| Li, BJ | 1 |
| Bai, H | 1 |
| Zhang, C | 1 |
| Han, C | 1 |
| Fan, YX | 1 |
| Li, YW | 1 |
| Dou, XG | 1 |
| Lin, KH | 1 |
| Chen, YL | 1 |
| Lin, PY | 1 |
| Hsieh, CE | 1 |
| Ko, CJ | 1 |
| Lin, CC | 1 |
| Ming, YZ | 1 |
| Chawla, PS | 1 |
| Kochar, MS | 1 |
| Beckebaum, S | 1 |
| Sotiropoulos, GC | 1 |
| Gerken, G | 1 |
| Cicinnati, VR | 1 |
| García Buey, L | 1 |
| González Mateos, F | 1 |
| Moreno Otero, R | 1 |
| Barreiro, P | 1 |
| Martín-Carbonero, L | 1 |
| García-Samaniego, J | 1 |
| Fontana, RJ | 2 |
| Amini-Bavil-Olyaee, S | 1 |
| Herbers, U | 1 |
| Sheldon, J | 1 |
| Luedde, T | 1 |
| Trautwein, C | 1 |
| Tacke, F | 1 |
| Montineri, A | 1 |
| Nigro, L | 1 |
| Chiarenza, A | 1 |
| Larocca, L | 1 |
| La Rosa, R | 1 |
| Iacobello, C | 1 |
| Di Raimondo, F | 1 |
| Fatuzzo, F | 1 |
| Liu, FJ | 1 |
| Liu, L | 1 |
| Zhou, TY | 1 |
| Lei, J | 1 |
| Xu, L | 1 |
| Liu, C | 1 |
| Chen, EQ | 1 |
| Tang, H | 1 |
| Poordad, F | 1 |
| Chee, GM | 1 |
| Dai, ZJ | 1 |
| Ye, C | 1 |
| Zhang, HY | 1 |
| Liu, ZG | 1 |
| Zhang, Z | 1 |
| Gong, HY | 1 |
| Finsterer, J | 1 |
| Ay, L | 1 |
| Mallet, V | 1 |
| Vallet-Pichard, A | 1 |
| Pol, S | 1 |
| Gou, YZ | 1 |
| Liu, B | 1 |
| Jiang, W | 1 |
| Yu, HT | 1 |
| Bai, XF | 1 |
| Dang, S | 1 |
| Gao, N | 1 |
| Zhang, X | 1 |
| Jia, X | 1 |
| Gaynor, JW | 1 |
| Cosstick, R | 1 |
| Giles, M | 1 |
| Visvanathan, K | 1 |
| Sasadeusz, J | 1 |
| García-Alonso, FJ | 1 |
| Martín-Mateos, RM | 1 |
| Moreira Vicente, V | 1 |
| Singal, AK | 1 |
| Kan, NY | 1 |
| Wu, MM | 1 |
| Dusheiko, G | 1 |
| Perrella, A | 1 |
| Lanza, AG | 1 |
| Santaniello, W | 1 |
| Pisaniello, D | 1 |
| Dicostanzo, G | 1 |
| Calise, F | 1 |
| Amato, G | 1 |
| Marcos, A | 1 |
| Cuomo, O | 1 |
| Huang, Y | 1 |
| Wu, H | 1 |
| Wu, S | 1 |
| Fu, D | 1 |
| Ma, Y | 1 |
| Shen, X | 1 |
| Morando, F | 1 |
| Rosi, S | 1 |
| Fasolato, S | 1 |
| Cavallin, M | 1 |
| Gola, E | 1 |
| Gatta, A | 1 |
| Angeli, P | 1 |
| Chen, R | 1 |
| Liu, SR | 1 |
| Zhang, SY | 1 |
| Tao, CJ | 1 |
| Hodge, RA | 1 |
| Niederau, C | 1 |
| Hou, JL | 1 |
| Sun, J | 1 |
| Wang, C | 1 |
| Warnatz, H | 1 |
| Scheiffarth, F | 1 |
| Wolf, F | 1 |
| Schmidt, HJ | 1 |
| Cote, PJ | 1 |
| Gerin, JL | 1 |
| Bryant, ML | 2 |
| Bridges, EG | 2 |
| Placidi, L | 2 |
| Faraj, A | 2 |
| Loi, AG | 1 |
| Pierra, C | 2 |
| Dukhan, D | 2 |
| Gosselin, G | 2 |
| Imbach, JL | 2 |
| Hernandez, B | 1 |
| Juodawlkis, A | 1 |
| Tennant, B | 1 |
| Korba, B | 1 |
| Cote, P | 1 |
| Marion, P | 1 |
| Cretton-Scott, E | 2 |
| Schinazi, RF | 1 |
| Sommadossi, JP | 2 |
| Hernandez-Santiago, B | 1 |
| Rodriguez-Orengo, J | 1 |
| Kaklamanis, E | 1 |
| Trichopoulos, D | 2 |
| Papaevangelou, G | 2 |
| Drouga, M | 2 |
| Karalis, D | 2 |
| Moritsugu, Y | 1 |
| Gold, JW | 1 |
| Wagner, J | 1 |
| Dodd, RY | 1 |
| Purcell, RH | 1 |
| Kaklamani, E | 1 |
| Papoutsakis, G | 1 |
| Masi, M | 1 |
| Paolucci, P | 1 |
| Timoncini, G | 1 |
| Fantini, MP | 1 |
| Chiodo, F | 1 |
| Franceschi, C | 1 |
| Wicks, RC | 1 |
| Kohler, PF | 1 |
| Singleton, JW | 1 |
| Cappel, R | 1 |
| Clinet, G | 1 |
| Thiry, L | 1 |
| Greeman, RL | 1 |
| Robinson, WS | 1 |
| Vyas, GN | 1 |
| Fiume, L | 1 |
| Bassi, B | 1 |
| Busi, C | 1 |
| Mattioli, A | 1 |
| Spinosa, G | 1 |
| Degrassi, A | 1 |
| Mariani, E | 1 |
| Roda, P | 1 |
| Miniero, R | 1 |
| Capelli, M | 1 |
| Honorati, MC | 1 |
| Astaldi, A | 1 |
| Facchini, A | 1 |
| Nordenfelt, E | 1 |
| Löfgren, B | 1 |
| Chattopadhyaya, J | 1 |
| Oberg, B | 1 |
| Laiwah, AA | 1 |
| Kissling, M | 1 |
| Speck, B | 1 |
| Doshi, J | 1 |
| Luisada-Opper, A | 1 |
| Leevy, CM | 1 |
| Millman, I | 1 |
| Agarwal, SS | 1 |
| Bugbee, SJ | 1 |
| Blumberg, BS | 1 |
| Loeb, LA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Mother-to-child Transmission of Hepatitis B Virus: a One Arm, Open Label Intervention Study to Estimate the Optimal Timing of Tenofovir (TDF) in Pregnancy[NCT02995005] | Phase 1/Phase 2 | 98 participants (Actual) | Interventional | 2018-05-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for thymidine and Hepatitis B
| Article | Year |
|---|---|
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?
Topics: Adenine; Administration, Oral; Antiviral Agents; Carcinoma, Hepatocellular; Fibrosis; Guanine; Hepat | 2014 |
Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis.
Topics: Antiviral Agents; Female; Hepatitis B; Humans; Infant, Newborn; Infectious Disease Transmission, Ver | 2014 |
Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
Topics: Adenine; Antineoplastic Agents; Antiviral Agents; Controlled Clinical Trials as Topic; Guanine; Hepa | 2016 |
What's new in clinical pharmacology and therapeutics.
Topics: Abatacept; Acetanilides; Amides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antipark | 2008 |
Hepatitis B and liver transplantation: 2008 update.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B Vaccines; Hu | 2009 |
[Interferon in hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Guanine; H | 2008 |
[Hepatitis B in patients with HIV infection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Deox | 2008 |
The impact of human immunodeficiency virus on viral hepatitis.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Emtricitab | 2011 |
Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding.
Topics: Adenine; Antiviral Agents; Breast Feeding; Female; Guanine; Hepatitis B; Hepatitis B virus; Hepatiti | 2011 |
[Pharmacological treatment of acute hepatitis B].
Topics: Acute Disease; Adenine; Antiviral Agents; Guanine; Hepatitis B; Humans; Lamivudine; Nucleosides; Org | 2012 |
Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combin | 2012 |
A meta-analysis of nucleos(t)ide analogues in patients with decompensated cirrhosis due to hepatitis B.
Topics: Antiviral Agents; Hepatitis B; Humans; Lamivudine; Liver Cirrhosis; Nucleosides; Nucleotides; Revers | 2013 |
Telbivudine/Torcitabine Idenix/Novartis.
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Drugs, Investigational; Hepatitis B; Hepatitis | 2004 |
7 trials available for thymidine and Hepatitis B
| Article | Year |
|---|---|
Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Disease Progression; DNA, Viral; Female; Guanin | 2014 |
Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study.
Topics: Adolescent; Adult; Antiviral Agents; China; DNA, Viral; Female; Hepatitis B; Hepatitis B Surface Ant | 2015 |
A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Topics: Adult; Antiviral Agents; China; DNA, Viral; Female; Guanine; Hepatitis B; Hepatitis B e Antigens; He | 2010 |
[Analysis of the prophylactic effect of nucleosides against reactivation of HBV in HBsAg-positive patients with non-hepatic tumors after chemotherapy].
Topics: Adult; Antineoplastic Agents; Antiviral Agents; Breast Neoplasms; Female; Follow-Up Studies; Guanine | 2010 |
The diagnostic value of ultrasound elastography in patients with hepatitis B virus infection: a prospective study.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Asian People; China; Demography; El | 2010 |
[Efficacy and safety of telbivudine in pregnant women to prevent perinatal transmission of hepatitis B virus].
Topics: Adult; DNA, Viral; Female; Hepatitis B; Hepatitis B virus; Humans; Infectious Disease Transmission, | 2012 |
[Efficacy of telbivudine in blocking the vertical transmission and the safety observation of discontinuing treatment time after delivery on mother infected with HBV].
Topics: Adult; Antiviral Agents; Female; Hepatitis B; Humans; Infectious Disease Transmission, Vertical; Mot | 2012 |
49 other studies available for thymidine and Hepatitis B
| Article | Year |
|---|---|
[A case report of severe edema in both lower limbs of hepatitis B patients with normal renal function induced by telbivudine].
Topics: Antiviral Agents; DNA, Viral; Edema; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Humans; | 2019 |
Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine.
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hep | 2021 |
Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels.
Topics: Adenine; Adult; Alanine Transaminase; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B; H | 2017 |
Prevention of mother-to-child transmission: the key of hepatitis B virus elimination.
Topics: Antiviral Agents; Female; Hepatitis B; Hepatitis B virus; Humans; Immunization Programs; Infant, New | 2018 |
Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; | 2013 |
Treatment with telbivudine for fulminant hepatitis B.
Topics: Acute Disease; Adult; Antiviral Agents; Female; Hepatitis B; Humans; Liver Failure, Acute; Telbivudi | 2013 |
In vivo antiviral activity of telbivudine against HIV-1: a case report.
Topics: Acute Disease; Adenine; Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis B | 2013 |
Comparison of telbivudine efficacy in treatment-naive patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Cholinesterases; Drug Resistance, Viral; | 2014 |
Therapy of acute and fulminant hepatitis B.
Topics: Antiviral Agents; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatiti | 2014 |
Lamivudine/telbivudine-associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion.
Topics: Adult; Aged, 80 and over; Antiviral Agents; Biopsy; DNA, Mitochondrial; Female; Hepatitis B; Humans; | 2014 |
[Retrospective analysis of the efficacy and safety of anti-hepatitis B virus drugs taken during pregnancy in women from the Guangdong Province].
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B; Hepatitis B virus; Humans; Infant; Infant, | 2014 |
Efficacy and safety of telbivudine treatment: an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection.
Topics: Adult; Antiviral Agents; Case-Control Studies; China; DNA, Viral; Female; Hepatitis B; Hepatitis B S | 2015 |
Should Evidence-based Medicine Be Used to Design Clinical Practice Guidelines for the Prevention of Perinatal Transmission of Hepatitis B Virus From Hepatitis B e Antigen-Positive Mothers?
Topics: Antiviral Agents; Female; Hepatitis B; Humans; Infectious Disease Transmission, Vertical; Male; Preg | 2015 |
Telbivudine in liver transplant recipients: Renal protection does not overcome the risk of polyneuropathy and myopathy.
Topics: Aged; Antiviral Agents; Diabetes Mellitus; Drug Substitution; End Stage Liver Disease; Female; Glome | 2015 |
Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; China; DNA, Viral; Drug Resistance, Viral; Female; Genetic Variati | 2015 |
A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; China; Female; Follow-Up Studies; Guanine; Hepatitis B; H | 2016 |
[Telbivudine for prevention of perinatal transmission in pregnant women infected with hepatitis B virus in immune-tolerant phase: a study of efficacy and safety of drug withdrawal].
Topics: Antiviral Agents; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Humans; Infant; In | 2016 |
A Follow-Up Study on the Renal Protective Efficacy of Telbivudine for Hepatitis B Virus-Infected Taiwanese Patients After Living Donor Liver Transplant.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Creatinine; Cross-Sectional Studies; End Stage Liver Dise | 2017 |
Hepatitis B: a "GLOBAL" health challenge.
Topics: Antiviral Agents; DNA, Viral; Global Health; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Nuc | 2009 |
The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
Topics: Adenine; Anti-HIV Agents; Cell Line, Tumor; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Gua | 2009 |
Telbivudine use in a patient affected by occult hepatitis B virus and B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Application of hepatitis B virus replication mouse model.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Resistance, Viral; Enzyme-Linked Immunosorbe | 2010 |
Viral resistance in hepatitis B: prevalence and management.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Genetic Testing; Genotype; Guanine; Hepatitis B; | 2010 |
Myotoxicity of telbivudine in pre-existing muscle damage.
Topics: Adult; Antiviral Agents; Creatine Kinase; Hepatitis B; Humans; Male; Muscle, Skeletal; Muscular Dise | 2010 |
Rhabdomyolysis in a 48-year-old man with hepatitis B-induced cirrhosis.
Topics: Acute Kidney Injury; Antiviral Agents; Fatal Outcome; Fibrosis; Hepatitis B; Humans; Male; Middle Ag | 2011 |
Dinucleotides containing 3'-S-phosphorothiolate linkages.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; Dinucleoside Phosphates; Endonucleases; Hepatitis B; He | 2011 |
Interruption of mother-to-infant transmission of hepatitis B: time to include selective antiviral prophylaxis?
Topics: Antiviral Agents; Developing Countries; Female; Hepatitis B; Humans; Infant; Infant, Newborn; Infect | 2012 |
Telbivudin as prophylaxis for hepatitis B virus recurrence after liver transplantation: a case series in single-center experience.
Topics: Adult; Case-Control Studies; Female; Hepatitis B; Humans; Liver Transplantation; Male; Middle Aged; | 2012 |
Severe acute hepatitis B in a treatment-naïve patient with antiviral drug resistant mutations in the polymerase gene.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Hepatitis B; Hepatitis B An | 2013 |
[New German and American guidelines for therapy of hepatitis B. Discrepancies and similarities].
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resistance, Viral; Drug Th | 2007 |
[Several important issues on drug resistance of hepatitis B virus].
Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis B; Hepatitis B virus; Humans; Nucleosides; Pyrim | 2007 |
Autoradiographic experiments concerning the importance of mononuclear cells in experimental hepatitis.
Topics: Animals; Autoradiography; Carbon Tetrachloride Poisoning; Hepatitis B; Liver; Lymphocytes; Mice; Thy | 1967 |
In vitro activation of woodchuck lymphocytes measured by radiopurine incorporation and interleukin-2 production: implications for modeling immunity and therapy in hepatitis B virus infection.
Topics: Animals; Antigens, Viral; Cells, Cultured; Culture Media; Disease Models, Animal; Epitopes; Hepatiti | 1995 |
Antiviral L-nucleosides specific for hepatitis B virus infection.
Topics: Animals; Anti-HIV Agents; Antiviral Agents; Bone Marrow Cells; Cell Line; Deoxyadenosines; Deoxycyti | 2001 |
Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Deoxycytidine; Ha | 2002 |
Letter: T lymphocytes in HBAg carriers and responders.
Topics: Antibodies, Viral; Carrier State; Female; Hepatitis B; Hepatitis B Antigens; Humans; Immune Adherenc | 1975 |
Hepatitis B core antigen. Detection of antibody by radioimmunoprecipitation.
Topics: Animals; Antibodies; Antibodies, Viral; Carrier State; Centrifugation, Density Gradient; Complement | 1975 |
T-lymphocytes and hepatitis B serology.
Topics: Carbon Radioisotopes; Female; Hepatitis B; Hepatitis B Surface Antigens; Humans; Lectins; Rosette Fo | 1978 |
[Chronic persistent HBsAG positive hepatitis in children. I. Subpopulations of T and B lymphocytes].
Topics: B-Lymphocytes; Child; Child, Preschool; Chronic Disease; Female; Hepatitis B; Hepatitis B Surface An | 1978 |
Thymus-derived lymphocytes in type B acute viral hepatitis and healthy carriers of hepatitis B surface antigen (HBsAg).
Topics: Carrier State; Cells, Cultured; Hepatitis B; Hepatitis B Antigens; Humans; Immune Adherence Reaction | 1975 |
[Letter: Demonstration of anti-ADN polymerase antibodies during serum hepatitis].
Topics: Antibodies; DNA Nucleotidyltransferases; Hepatitis B; Humans; Immunoglobulin G; Immunoglobulin M; Th | 1975 |
A sensitive test for antibody against the hepatitis B core antigen (anti-HB-c).
Topics: Animals; Antibodies; Carrier State; Centrifugation, Density Gradient; DNA Nucleotidyltransferases; G | 1975 |
Drug targeting in antiviral chemotherapy. A chemically stable conjugate of 9-beta-D-arabinofuranosyl-adenine 5'-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells.
Topics: Animals; Arabinonucleotides; Bone Marrow; DNA; Female; Hepatitis B; Intestinal Mucosa; Liver; Mice; | 1986 |
Specific lymphocyte proliferative response in vitro after cDNA HBsAg immunization.
Topics: Adult; Concanavalin A; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; He | 1989 |
Inhibition of hepatitis B virus DNA polymerase by 3'-azido-3'-deoxythymidine triphosphate but not by its threo analog.
Topics: Antiviral Agents; Carrier State; Dideoxynucleotides; Hepatitis B; Hepatitis B virus; Humans; Nucleic | 1987 |
Lymphocyte transformation by Australia antigen.
Topics: Antibody Formation; Antigens; Carbon Isotopes; Complement Fixation Tests; Hepatitis A; Hepatitis B; | 1971 |
Lymphocyte transforming activity in the serum of patients with hepatic disease.
Topics: Autoradiography; Cholestasis; Culture Techniques; Cytidine; DNA Replication; Globulins; Hepatitis; H | 1971 |
Microsomal pentobarbital hydroxylase activity in acute viral hepatitis.
Topics: Biopsy; Carbon Isotopes; Hepatitis A; Hepatitis B; Hepatitis B Antigens; Humans; Liver Function Test | 1972 |
Lymphocyte transformation and hepatitis. II. Lack of direct in vitro inhibition by purified Australia antigen.
Topics: Cold Temperature; DNA Nucleotidyltransferases; DNA Replication; Hepatitis A; Hepatitis B; Hepatitis | 1971 |